Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Down 38.0% in June

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the recipient of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 20,835 shares, a decrease of 38.0% from the June 15th total of 33,610 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 77,001 shares, the days-to-cover ratio is presently 0.3 days.

Curanex Pharmaceuticals Trading Down 0.1%

CURX opened at $0.22 on Friday. Curanex Pharmaceuticals has a 12 month low of $0.20 and a 12 month high of $9.18. The company has a market cap of $6.18 million and a PE ratio of -0.80. The company has a 50 day moving average of $0.29 and a 200 day moving average of $0.36.

Curanex Pharmaceuticals (NASDAQ:CURX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter.

Institutional Investors Weigh In On Curanex Pharmaceuticals

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new position in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 64,067 shares of the company’s stock, valued at approximately $46,000.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.